Efficient active hydrogen delivery for drug-free radiation enteritis therapy in mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41107261.
- Also identified by DOI 10.1038/s41467-025-64270-9 and PMC identifier 12534411.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiation enteritis, affecting over 90% of pelvic/abdominal radiotherapy patients, is primarily caused by radiation-induced reactive oxygen and nitrogen species (RONS). Active hydrogens, with broad-spectrum RONS scavenging ability, show radioprotective potential but face delivery challenges due to the intestinal mucus barrier and short lifespan. Here, we show drinkable, self-thermophoretic sodium alginate/chitosan oligosaccharide-coated hydrogenated molybdenum oxide nanomachines (H<sub>x</sub>MoO<sub>3</sub>@SA@COSs) that exhibit near-infrared (NIR)-driven directional motility and sustained active hydrogen release. In a male mouse model of radiation enteritis, H<sub>x</sub>MoO<sub>3</sub>@SA@COSs overcome the mucus barrier, prolong intestinal retention, and deliver active hydrogen to injury sites, enabling precise enteritis therapy. Beyond RONS scavenging, the released hydrogen induces anti-inflammatory macrophage polarization, increases goblet cell abundance, and modulates gut microbiota, promoting intestinal repair. This hydrogen-based, drug-free strategy demonstrates superior efficacy in treating radiation enteritis.
Medical subject headings
- Hydrogen
- Enteritis
- Radiation Injuries